江苏亚虹医药科技股份有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients 2021-06-15 08:46
Asieris and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of APL-1202 and Tislelizumab 2021-05-06 20:33
Asieris Announces First Patient Administration in the Global Phase III Clinical Trial for APL-1702 2020-11-11 17:08
Asieris Announces Approval of its Phase III Trial of a Novel Single Oral Agent as First-line Treatment for Non-Muscle Invasive Bladder Cancer (NMIBC) 2020-11-05 13:59
Asieris' APL-1501 Approved for Phase I Clinical Trial in Australia 2020-10-29 09:35
Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL) 2020-07-08 22:00
Asieris Wins Questex's Fierce Innovation Awards - Life Sciences Edition 2019 2019-12-19 13:51
Asieris and Photocure Enter into a License Agreement for World-Wide Development and Commercialization of Cevira® 2019-07-02 21:40
Asieris Announces Completion of Enrollment for its US APL-1202 Phase Ib Clinical Trial 2019-06-24 09:00
1 2 3